Arab Tunisian Bank (BVMT:ATB)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions TND. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	31.29	-0.16	29.6	-61.44	12.46
Depreciation & Amortization	22.08	20.5	16	20.59	16.29
Other Operating Activities	573.23	201.48	-73.71	-353.91	393.12
Operating Cash Flow	626.6	221.82	-28.12	-394.75	421.88
Operating Cash Flow Growth	182.48%	-	-	-	-
Capital Expenditures	-94.12	-38.74	-41.21	-43.87	-28.78
Investment in Securities	-56.81	294.95	61.47	-110.16	79.35
Other Investing Activities	76.58	80.42	84.03	81.48	77.88
Investing Cash Flow	-74.35	336.64	104.29	-72.55	128.45
Long-Term Debt Issued	5.04	57.01	47.47	40	99.08
Long-Term Debt Repaid	-	-	-468.98	-77.72	-31.18
Net Debt Issued (Repaid)	5.04	57.01	-421.51	-37.72	67.9
Issuance of Common Stock	-	-	-	70	-
Common Dividends Paid	-6.13	-4.12	-3.93	-1.46	-0.67
Other Financing Activities	-105.77	-35.47	213.94	256.89	-32.18
Financing Cash Flow	-106.86	17.43	-211.5	287.71	35.06
Net Cash Flow	445.39	575.88	-135.33	-179.59	585.39
Free Cash Flow	532.48	183.08	-69.33	-438.62	393.1
Free Cash Flow Growth	190.84%	-	-	-	-
Free Cash Flow Margin	166.90%	67.75%	-24.93%	-240.16%	176.73%
Free Cash Flow Per Share	4.16	1.39	-0.54	-4.38	3.91
Cash Income Tax Paid	11.37	15.98	4.41	15.67	-2.59

Source: S&P Global Market Intelligence. Banks template. Financial Sources.